The global wound care biologics market was worth US$ 1.40 Billion in 2018. Wound care biologics refer to drugs extracted or semi-synthesized from natural sources which are used for controlling and healing infections. Wound healing is a complex process involving inflammation, accumulation of fibrous tissue, deposition of collagen, formation of epithelial cell layers and other disruptions. Biologic wound healing treatments possess the ability to restore the natural repair mechanism through active biological agents. For instance, plant-derived active biomolecules with antimicrobial, anti-inflammatory or antioxidant properties have proven efficacious in advancing the wound-healing process. Some of the recent technological advancements made in the field of wound healing include skin substitutes, bio-membranes, scaffolds, hydroconductive dressings and biologics.
Chronic skin wounds can be caused due to burns, skin cancers, infections, trauma or an underlying medical condition such as diabetes. With the growing prevalence of these ailments along with the expanding geriatric population, there has been a rise in the demand for treatments that can accelerate wound healing and facilitate a speedy recovery. Along with this, several initiatives have been undertaken by governments across the globe to create awareness about the benefits of wound care biologics among patients. Apart from this, manufacturers are also developing next-generation, cost-effective and high-quality biologics to make them more accessible. Moreover, many research and healthcare centers are entering into partnerships to modernize wound care treatments and develop innovative drugs for healing wounds. For example, researchers are focusing on integrating antimicrobial compounds into the wound dressing itself. These materials combine traditional wound dressings such as hydrogels or foams with antimicrobial compounds such as betaine, silver, chitin, or polyhexamethylene biguanide. Looking forward, IMARC Group expects the market to reach a value of US$ 2.35 Billion by 2024, registering a CAGR of around 9% during 2019-2024.
The report has also analysed the competitive landscape of the market with some of the key players being Smith & Nephew, Mölnlycke Health Care, Integra lifesciences, Osiris Therapeutics, Avita Medical, ConvaTec Group, Cytori Therapeutics, Mylan, Johnson & Johnson, Leap Therapeutics, Nuo Therapeutics, Mallinckrodt, Wright Medical, Mimedx Group, Solsys Medical, etc.
Key Questions Answered in This Report:
REACH OUT TO US
Call us on
( US: +1-631-791-1145 )
( UK: +44-702-409-7331 )
( India: +91-120-433-0800 )
Drop us an email at